Objectives: The aim of this study was to evaluate the impact of smoking in patients with left ventricular dysfunction.
Background: The impact of smoking in patients with left ventricular dysfunction has not been well-studied.
Methods: We compared the incidence of death, hospitalization due to heart failure and myocardial infarction (MI) in current smokers to ex-smokers of < or =2 years and ex-smokers of >2 years duration to never-smokers among participants of the Study Of Left Ventricular Dysfunction (SOLVD) Prevention and Intervention trials. Participants all had left ventricular ejection fraction (LVEF) <35% and follow-up was over a mean of 41 months.
Results: Complete smoking status and outcome data were available in 6,704 subjects. There were 1,562 current smokers, 1,317 ex-smokers of < or =2 years, 2,354 ex-smokers of >2 years and 1,471 never-smokers. After adjusting for baseline differences of age, LVEF, race and etiology of heart failure, current smoking was associated with a significantly increased all-cause mortality (relative risk [RR]: 1.41, 95% confidence interval [CI]: 1.25 to 1.58, p < 0.001) compared with ex-smokers and never-smokers. The incidence of death or recurrent congestive heart failure requiring hospitalization or MI was significantly greater (RR: 1.39, 95% CI: 1.26 to 1.52, p < 0.001) in current smokers compared with ex-smokers and never-smokers. There were no significant differences in the number of deaths or hospitalizations due to heart failure between ex-smokers and never-smokers. This effect was consistent across both the SOLVD Prevention and Treatment trials.
Conclusions: Current smoking is a powerful independent predictor of morbidity (recurrent heart failure and MI) and mortality in patients with left ventricular dysfunction. Quitting smoking appears to have a substantial and early effect (within two years) on decreasing morbidity and mortality in patients with left ventricular dysfunction, which is at least as large as proven drug treatments recommended in patients with left ventricular dysfunction.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0735-1097(01)01195-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Left ventricular hypertrophy in young hypertensives: the possible crosstalk of mTOR and angiotensin-II -a case-control study.
BMC Cardiovasc Disord
January 2025
Cardio/Endo-metabolic and Microbiome Research Unit, Department of Physiology, College of Medicine and Health Sciences, Afe Babalola University, Ado-Ekiti, 360101, Nigeria.
Background: Hypertension is a major cause of cardiac dysfunction. The earliest manifestation is left ventricular remodeling/hypertrophy. The occurrence of adverse cardiac remodeling and outcomes occurs irrespective of age in blacks.
View Article and Find Full Text PDFObserver- and sequence variability in personalized 4D flow MRI-based cardiovascular models.
Sci Rep
January 2025
Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.
Subject-specific parameters in lumped hemodynamic models of the cardiovascular system can be estimated using data from experimental measurements, but the parameter estimation may be hampered by the variability in the input data. In this study, we investigate the influence of inter-sequence, intra-observer, and inter-observer variability in input parameters on estimation of subject-specific model parameters using a previously developed approach for model-based analysis of data from 4D Flow MRI acquisitions and cuff pressure measurements. The investigated parameters describe left ventricular time-varying elastance and aortic compliance.
View Article and Find Full Text PDFEmpagliflozin Ameliorates the Oxidative Stress Profile in Type 2 Diabetic Patients with Heart Failure and Reduced Ejection Fraction: Results of a Randomized, Double-blind, Placebo-controlled Study.
Rev Recent Clin Trials
January 2025
Department of Clinical Pharmacy, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran.
Introduction: In the present study, we evaluated the impact of empagliflozin on serum levels of oxidative stress parameters in individuals with type 2 diabetes (T2DM) who also suffer from heart failure with Reduced Ejection Fraction (HFrEF).
Methods: In this prospective, single-center clinical trial, 80 patients with T2DM and HFrEF, stabilized on guideline-directed heart failure therapy and classified as New York Heart Association functional (NYHA) functional classes II or III, were randomized to receive either empagliflozin (10 mg/daily) or a matching placebo for a duration of 12 weeks. Serum levels of malondialdehyde (MDA), along with the activity of superoxide dismutase (SOD) and glutathione peroxidase (GPx), were measured at baseline and after the 12-week treatment period.
Routine Left Ventricular Unloading During Venoarterial Extracorporeal Membrane Oxygenation-A Therapeutic Conundrum.
J Cardiothorac Vasc Anesth
December 2024
Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy. Electronic address:
Assessing outcomes of acute myocarditis in Saudi Arabia: A retrospective tertiary center experience.
Saudi Med J
January 2025
From the College of Medicine (Bin Abdu, Assiri, Altasan, Alghamdi, Alshelawy, Alqahtani, Aljabr, Alnahdi, Alhamzani, Alghamdi, Alzahrani, Alshahrani, Alzahrani, Alshalawi), King Saud Bin Abdulaziz University for Health Sciences; from the Department of Medicine (Bin Abdu, Assiri, Altasan, Alghamdi, Alshelawy, Alqahtani, Aljabr, Alnahdi, Alhamzani, Alghamdi, Alzahrani, Alshahrani, Alzahrani, Alshalawi), King Abdullah International Medical Research Center; and from the Emergency Department (Alshalawi), King Abdulaziz Medical City Riyadh, Kingdom of Saudi Arabia.
Objectives: To assess the clinical course and long-term outcomes of complicated and uncomplicated AM in Saudi Arabia. Acute myocarditis (AM) can have different presentations and outcomes based on different factors, one of which is left ventricular ejection fraction (LVEF).
Methods: Data from 382 patients with suspected AM, admitted between January 2016 and October 2023, were reviewed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!